CATALENT INC. DL-,01/ US1488061029 /
5/23/2024 1:46:51 PM | Chg. +0.30 | Volume | Bid1:46:51 PM | Ask1:46:51 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
50.59EUR | +0.60% | - Turnover: - |
50.59Bid Size: - | 51.12Ask Size: - | 9.19 bill.EUR | - | - |
GlobeNewswire
5/17
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of...
GlobeNewswire
5/14
Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
GlobeNewswire
5/8
Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cance...
GlobeNewswire
4/26
TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger – CTLT, MGRC, CHRD, HRT
GlobeNewswire
4/11
Robbins LLP is Investigating the Acquisition of Catalent, Inc. (CTLT) by Novo Holdings
GlobeNewswire
4/4
TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger – NS, CTLT, SCX, EVBG
GlobeNewswire
3/7
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Catalent, Inc. -...
GlobeNewswire
3/1
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of...
GlobeNewswire
3/1
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of...
GlobeNewswire
2/28
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Catalent, Inc. -...